Q32 BIO INC. SUPPORT AGREEMENTSupport Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 16th, 2023 Company Industry JurisdictionTHIS SUPPORT AGREEMENT (this “Agreement”), dated as of November 16, 2023 is made by and among Homology Medicines, Inc., a Delaware corporation (“Homology”), Q32 Bio Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of the Company.
Employment AgreementEmployment Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 16th, 2023 Company Industry JurisdictionThis Employment Agreement (this “Agreement”), dated as of November 16, 2023, is made by and between Homology Medicines, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Charles Michaud, Jr. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and effective as of November 16, 2023 (the “Effective Date”).
Amended and Restated Employment AgreementSeparation Agreement and Release • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 16th, 2023 Company Industry JurisdictionThis Amended and Restated Employment Agreement (this “Agreement”), dated as of November 16, 2023, is made by and between Homology Medicines, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Paul Alloway, Ph.D., J.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and effective as of November 16, 2023 (the “Effective Date”).
CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN HOMOLOGY MEDICINES, INC. and EQUINITI TRUST COMPANY, LLC, as Rights Agent Dated as of November 16, 2023Contingent Value Rights Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 16th, 2023 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of November 16, 2023, is entered into by and between Homology Medicines, Inc., a Delaware corporation (“Homology”), and Equiniti Trust Company, LLC, a New York limited liability company (“EQ”), as initial Rights Agent (as defined herein).
LOCK-UP AGREEMENTMerger Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 16th, 2023 Company Industry
CONSULTING AGREEMENTConsulting Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 16th, 2023 Company Industry JurisdictionTHIS CONSULTING AGREEMENT (the “Agreement”), effective as of November 16, 2023 (the “Effective Date”), is made by and between Homology Medicines, Inc., a Delaware corporation (the “Company”), and W. Bradford Smith (“Consultant”).
AGREEMENT AND PLAN OF MERGER by and among: HOMOLOGY MEDICINES, INC.; KENOBI MERGER SUB, INC.; and Q32 BIO INC. Dated as of November 16, 2023Agreement and Plan of Merger • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 16th, 2023 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of November 16, 2023, by and among HOMOLOGY MEDICINES, INC., a Delaware corporation (“Homology”), KENOBI MERGER SUB, INC., a Delaware corporation and a direct, wholly owned subsidiary of Homology (“Merger Sub”), and Q32 BIO INC., a Delaware corporation (“Q32”). Certain capitalized terms used in this Agreement are defined in Section 1.1.
HOMOLOGY MEDICINES, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • November 16th, 2023 • Homology Medicines, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 16th, 2023 Company IndustryThis SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into effective as of November 16, 2023, by and between Homology Medicines, Inc. (the “Company”) and W. Bradford Smith (“Executive,” and, together with the Company, the “Parties”).